Phosphatidylserine (PS) and TYRO3-AXL-mertk (TAM) receptor tyrosine kinase (RTK) level detection on the surface of extracellular vesicle (EV) in chronic lymphocytic leukemia (CLL)
Patent Information
- Application Number
- PCT/TR2024/050690
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-06-14
- Publication Date
- 2024-12-26
Smart Images

Figure IMGF000009_0001 
Figure IMGF000010_0001 
Figure IMGF000010_0002
Abstract
Description
[0001] PHOSPHATIDYLSERINE (PS) AND TYRO3-AXL-MERTK (TAM) RECEPTOR TYROSINE KINASE (RTK) LEVEL DETECTION ON THE SURFACE OF EXTRACELLULAR VESICLE (EV) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
[0002] Technical Field
[0003] This invention involves the detection of phosphatidylserine (PS) and Tyro3-Axl-Mertk (TAM) receptor tyrosine kinase (RTK) levels on the surface of extracellular vesicle (EV) in chronic lymphocytic leukemia (CLL) patients. It also paves the way for the development of blocking agents specific for PS and TAM RTKs and / or development of methods that enable their removal from the blood.
[0004] Prior Art
[0005] In the state of the art, there are no studies to detect PS and TAM molecule levels on the surface of EVs for CLL patients.
[0006] Document numbered W02017059280A1 covers treatments using pyrimidine compounds consisting of combinations of pan-TAM or Mer / Axl dual receptor tyrosine kinase inhibitory agents in combination with immune checkpoint inhibitors in various types of cancer. However, these are not studies conducted on CLL and the surface of EVs.
[0007] Document numbered WO2018187227A1 describes treatments using checkpoint inhibitor antibodies, such as Bavituximab, in combination with immuno-oncology (IO) agents. However, the studies are within the scope of solid tumors and there are no studies on the use of these agents in CLL and other hematological malignancies.
[0008] Objects and Brief Description of the Invention
[0009] The aim of the present invention is to detect increased levels of PS and TAM RTKs on the surface of EV in CLL patients compared to healthy volunteers. Thus, it may contribute to the development of various treatment methods such as neutralizing EVs by using specific blocking agents for these receptors or removing them from the blood with special selective columns. Thanks to the invention, it has been determined that TAM RTK levels are increased in CLL patients. Accordingly, blocking agents can be developed for TAM RTKs located on the surface or they can be removed from the blood by passing them through columns containing antigens that bind to EVs and TAM RTKs.
[0010] Detailed Description of the Invention
[0011] The method carried out to achieve the object of the present invention is described in the attached figures.
[0012] Figure 1 Schematic views of beads coated with CD9 antibody (a), purified EVs (b), CD81 antibodies (c) and the complex suitable for flow cytometry application (d).
[0013] Figure 2 The plot of EV particle size and concentration for 1 patient.
[0014] Figure 3 Gate uptake plot for samples containing CD81 (labelled) relative to the isotype control sample containing the bead-CD9-EV complex (unlabelled).
[0015] Figure 4 Flow cytometric analysis plot of EVs of isotype control (a), CD81-labelled CLL group (b) and CD81 -labelled healthy group (c).
[0016] Figure 5 Comparative statistical analysis plot of the amount of EVs in CLL patients and healthy group.
[0017] Figure 6 Flow cytometry analysis plot of isotype control curve showing PS receptor levels in EVs (a), receptor levels in CLL patients (b) and receptor levels in healthy volunteers (c).
[0018] Figure 7 Flow cytometry analysis plot of isotype control curve showing Mertk receptor levels in EVs (a), receptor levels in CLL patients (b) and receptor levels in healthy volunteers (c).
[0019] Figure 8 Flow cytometry analysis plot of isotype control curve showing Tyro3 receptor levels in EVs (a), receptor levels in CLL patients (b) and receptor levels in healthy volunteers (c).
[0020] Figure 9 Flow cytometry analysis plot of isotype control curve showing Axl receptor levels in EVs (a), receptor levels in CLL patients (b) and receptor levels in healthy volunteers (c).
[0021] Figure 10 Comparative statistical analysis plot of PS receptor levels in CLL group and healthy group.
[0022] Figure 11 Comparative statistical analysis plot of Mertk receptor levels in CLL group and healthy group. Figure 12 Comparative statistical analysis plot of Tyro3 receptor levels in CLL group and healthy group.
[0023] Figure 13 Comparative statistical analysis plot of Axl receptor levels in CLL group and healthy group.
[0024] Within the scope of this study, EVs were purified from plasma obtained from the blood of patients and healthy volunteers, and their characterization was confirmed with CD9 (cluster of differentiation 9) and CD81 (cluster of differentiation 81) markers specific to EVs. Carboxy latex beads were bound to surface receptors on EVs and the bead-EV complex was detected by flow cytometry. When the results were compared, it was determined that TAM RTK levels were significantly increased on the surface of EVs in patients compared to healthy volunteers. The method applied accordingly, essentially comprises the process steps purifying EVs from the plasma to be measured,
[0025] - binding of CD9 antibodies to carboxy latex beads,
[0026] - binding of the EVs to the carboxy latex beads, adding measurement antibodies that bind to target membrane proteins to the bead- CD9-EV complexes, determining measurement antibody levels by flow cytometry for the bead-CD9- EV-measurement antibody complex.
[0027] Within the scope of the invention, carboxy latex beads readily available in the market can be used. As CD9 marker is specific for EVs, it enables EVs to form complexes by binding to the beads.
[0028] Within the scope of the invention, CD81 protein on the surface of EVs and PS and TAM RTK-related antibodies can be labeled and analyzed flow cytometri technique.
[0029] The measurement antibodies may be selected or modified to display fluorescent behaviour.
[0030] With the invention, the measurement of EV membrane protein levels, especially receptor levels, can be performed by flow cytometry by forming complexes on the order of nanometres via carboxy latex beads. In this study, it was determined that TAM RTK levels on the surface of EVs increased significantly in CLL patients. The finding obtained will pave the way for the new treatment methods in which blocking agentsspecific to these receptors are developed and / or new techniques that enable the separation of these molecules from blood with special columns.
[0031] An exemplary embodiment of the invention for determining PS and TAM RTK levels in relation to CLL is described below.
[0032] Purification of EVs
[0033] For EV purification, qoriginal EV isolation kit (qoriginalRack, qoriginal, 500pl, IzonScience, New England) was used according to the manufacturer's instructions. The special feature of this kit is that it purifies EVs using size exclusion chromatography technique by retaining them on special columns.
[0034] This technique separates extracellular vesicles (EVs) from complex bioliquids according to their size and membrane structure. It can rapidly and efficiently purify EVs from various biological materials such as urine, plasma, cell culture supernatant and bronchoalveolar liquid (BAL). The working principle of the columns is based on the fact that large molecules pass through the column in the early process without entering the pore whereas, small molecules in contrast, enter the pores and are filtered from the column at a later time to obtain EVs. For EV purification from plasma, columns of 35 nm size were selected for separation. This column, which is used for particles in the size range of 35-350 nm, was preferred because it is effective in selecting molecules of 110 nm and below.
[0035] For purification, plasma samples obtained by centrifugation from patients and healthy subjects and qEV columns were brought to room temperature 1 hour before application. Samples dissolved at room temperature (500 pl / tube) were centrifuged at 1500 g for 10 min after vortexing. The supernatants were transferred to a clean tube and debris was removed. After a second centrifugation at 20,000 g for 30 min, the supernatants were transferred to clean tubes and samples were prepared for purification on the columns.
[0036] After the columns were placed in the column holder, the upper and lower caps were opened respectively and empty falcon tubes (15 ml) were placed under them. When the liquid in the column approached the column surface, 1.5 column volumes (~15 ml) of phosphate buffered saline (PBS) was added. When the PBS approached the column surface, the sample was loaded onto the column. After passing into the column, 3.5 ml was considered as waste volume and collected in the bottom falcon and quickly replaced by a clean ependorf tube (1.5 ml) to collect the EVs. After 1 ml of purified EVs were collected in this tube, they were divided into clean tubes with 250 pl each. To be used in subsequent tests, they were first rapidly frozen in liquid nitrogen for 1-2 min and then placed in -80 °C cabinets for long-term storage. After the EV purification process in a sample was completed, 1.5 volumes of PBS was passed through the column by placing a falcon tube in the bottom again. After the isolations were completed, 1 volume of 0.05% sodium azide was passed and the column was removed to +4 °C by closing the upper and lower screws as soon as the upper chamber was empty. In case of blockage in the columns, they were treated with sodium hydroxide.
[0037] Preparation of samples for flow cytometry
[0038] Due to the very small size of EVs, measurements can be performed by first coating CD9 marker on special carboxy latex beads (Biolegend, cat no# 312102) and then binding EVs to this complex. The coating process was a stepwise process lasting 3 days and flow cytometry evaluation was performed on the 3rd day.
[0039] On the first day, 20 pl beads were added into 100 pl PBS and centrifuged at 20.000 g for 10 min. After discarding the supernatant, 40 pl CD9 antibody was added and homogenised by pipetting. The volume was topped up to 100 pl with PBS and incubated in the rotator for 30 min. Thus, bead-CD9 binding was achieved, but for a more efficient binding, it was left to incubate overnight at +4 °C in the rotator. At the same time, 1 tube (250 pl) of each purified and cryopreserved EV samples to be bound the next day was moved from -80 °C to +4 °C for overnight thawing.
[0040] On the second day, the tube containing bead-CD9 was centrifuged at 20.000 g for 10 min, the supernatant was discarded and the pellet was dissolved in 1 ml PBS containing 5% BSA (bovine serum albumin). Incubated in the rotator at +4 °C for 4 hours. After centrifugation again at the same speed, the pellet was dissolved in 300 pl of PBS containing 1% BSA. For each sample from 25 patients and 15 healthy donors, 6 pl of this mixture was added to each sample tube containing 250 pl of purified EV. The volume of 256 pl in each tube was topped up to 300 pl with PBS containing 1% BSA. After incubating for 30 min in the rotator, the volume was topped up to 500 pl and left to incubate at +4 °C overnight.
[0041] On the third day, all samples (40 in total) were centrifuged at 10.000 g for 10 min and the supernatant was discarded. The pellet was resuspended in PBS containing 1% BSA and 10 pl of the bead-CD9-EV complex was added to each of 2 tubes to be used for characterization (unlabelled isotype control sample and CD81 labelled sample). The unlabelled tubes (isotype control) were used as a control group for the analysis of samples in CD81 -labelled tubes.
[0042] At this stage, CD81 labelling was performed for characterization and experiments continued. The remainder of the prepared bead-CD9-EV complex stock was also reserved for the measurement of PS and TAM RTK levels in a flow cytometry device. These assays are discussed in detail in the next section.
[0043] A stock containing 1 pl / test of CD81 antibody was prepared for use in the characterization test. This stock was prepared in 450 pl by adding 45 pl of antibody to 405 pl of PBS containing 1% BSA for a total of 45 samples against the risk of pipetting error for 40 samples. For each sample, 10 pl of this stock was added to a tube containing 10 pl of beads-CD9-EV. The tubes were topped up to 50 pl with PBS containing 1% BSA and left to incubate for 2 hours at room temperature and in the dark. At the end of incubation, the volume was topped up to 150 pl and readings were taken in the flow cytometry device.
[0044] Determination of PS and TAM RTK levels in EVs
[0045] For the determination of PS and TAM RTK levels in EVs by flow cytometry method, the bead-CD9-EV complex was used from the stock prepared as described above for characterization tests, with the difference that antibodies to be studied with target receptors instead of CD81 were added on day 3. For each sample, 10 pl of bead-CD9-EV complex was dispensed into tubes and each antibody was prepared as stock according to the user instructions. Mertk (Biolegend, cat no# 367607) antibody was prepared and applied in the same way as CD81 antibody.
[0046] Annexin V (TONBO) was prepared in the same way as CD81 and Mertk antibody, but instead of PBS containing 1% BSA, annexin binding solution was used for dilutions. This solution was diluted to 1 :6 with distilled water (225 pl annexin binding solution and 1125 pl distilled water). After adding 10 pl of annexin V antibody, 1 pl / test for each sample, the volume was topped up to 50 pl with annexin binding solution. After 2 hours of incubation at room temperature and in the dark, the volume of the samples was topped up to 150 pl with annexin binding solution prepared at a ratio of 1 : 10 (450 pl annexin binding solution and 4050 pl distilled water) and analysis were taken on the flow cytometry device.
[0047] Tyro3 (R&D, anti h-Tyro3 / DTK cat no# MAB859) and Axl (R&D, anti h-Axl cat no# MAB154) RTK readings were performed after labelling with secondary antibody (Biolegend, cat no# 406607). Firstly, stocks of Tyro and Axl antibodies were prepared in the same way as the other antibodies (same as Mertk ab; 0.5 pl / test). For each sample, 10 pl of the antibody to be studied was added to the tubes in which 10 pl of bead-CD9-EV complex was dispensed (Tyro for Tyro, Axl for Axl). The tubes were topped up to 50 pl with PBS containing 1% BSA and left to incubate for 2 hours at room temperature and in the dark. During this time, the secondary antibody to be used was prepared. For this purpose, 1000 pl of secondary antibody was prepared as 0.2 pl / test (20 pl antibody was dissolved in 980 pl PBS). After 2 hours of incubation, 10 pl of the secondary antibody was dispensed into each tube. The final volume was topped up with PBS to 160 pl and analysis were taken in the flow cytometry device.
[0048] EV characterization by flow cytometry was performed by the analysis of EVs labelled with EV-specific markers CD9 (ELK, cat no# ESI 999) and CD81 (Elabscience, cat no# E-A- F1073D) on a flow cytometry device (ACEA NovoCyte, ACEA Biosciences, Inc.).
[0049] In order to verify the characterization results obtained by flow cytometry according to the method of the invention, characterization was also performed by qNano particle measurement. Particle size measurement for EV characterization was performed by tunable resistive pulse sensing (TRPS) method with qNano (qNano, Izon, UK) device. The qNano device allows the measurement of the particle change in a nanopore due to electrophoresis without any labelling.
[0050] Before measuring with the qNano device, the measurement electrolyte, wetting, and coating solutions were prepared according to the user instructions. Before the measurement of the samples, the instrument was calibrated with CPC100B (Izon) calibration beads which diluted to 1 / 5000. Afterwards, particle counting in the samples was carried out with the NP100 pore, which has a measurement range of 50-330 nm and a pore diameter of 100 nm, until 500 particles were counted. The data were simultaneously transferred to the "Izon Control Suit v.3.4" software on the computer connected to the device and analysed.
[0051] Measurement results
[0052] The studies carried out to demonstrate the effectiveness of the method according to the invention are described below.
[0053] As a patient group, 25 CLL patients (11F / 14E) with Rai stage (0-1) and a median age of 61 years (38-93 years) were included in the study. Patient characteristics and clinical information are summarised in Table 1.
[0054] Table 1 - Patient characteristics and clinical information
[0055] In addition, 15 healthy donors (11F / 4E) with a median age of 37 years (22-55 years) participated in the study as a control group. The characteristics of the healthy donors are given in Table 2.
[0056] Table 2 - Characteristics of healthy persons EV Characterisation Results
[0057] EVs purified on qEV columns were analysed on qNano Gold device for determination of size and quantity. The data for each patient were analysed with the "Izon Control Suit v.3.4" programme on the computer connected to the device. The plot showing particle concentration and distribution for 1 patient is shown in Figure 2. In addition, when the particle size and density were analysed in the 80-150 nm and 150-300 nm ranges, it was observed that 80-150 nm sized EVs were over 80%. The particle sizes mentioned are also shown in Table 3.
[0058] Table 3 - 80-150 nm and 150-300 nm sized particle percentage (%) values
[0059] For flow cytometry analysis, firstly, analysis of the isotype control tube containing only the bead-CD9-EV complex (unlabelled) were taken and recorded. Then, readings of the CD81- containing (labelled) tubes were also taken and each sample was gated and analysed according to the unlabelled tube. Gating is shown in Figure 3.
[0060] Figure 4 shows PE-H fluorescence plots corresponding to EVs of isotype control (a) and CD81-labelled healthy subjects (c). The patient (b) plots with similar ratios (p=0.2245) are also shown. Accordingly, the overlapping of the patient and healthy person samples is due to their similar quantities. In addition, the fact that both groups are at least one log or more away from the isotype control in the horizontal plane indicates that the patient and healthy person samples carry the EV-specific CD81 marker. This confirms the EV content of the material obtained. The relevant statistical analysis is also presented in Figure 5.
[0061] As a result of the analysis performed by flow cytometry, PS and TAM RTK levels in patients and healthy subjects were evaluated on the surface of EVs according to the unlabelled isotype control tube. The curves for the unlabelled sample (a), the curves showing the molecule levels in patients (b) and the curves showing the molecule levels in healthy subjects (c) are presented in Figures 6 to 9 as a comparative analysis (overlay) for each molecule.
[0062] GraphPad Prism 9 software was used for statistical analysis of PS and TAM RTK levels on the surface of EVs of patients and healthy subjects. Due to different sample numbers, Student's T test, Mann-Whitney U test 2-tailed analysis were applied by selecting nonparametric group. p<0.05 value was defined as a significant difference according to the established hypothesis. Accordingly, the level of PS molecule was found to be significantly lower in patients than in healthy subjects (p<0.0001). On the other hand, when each of the TAM RTKs were analysed separately, a significant increase was found in patients compared to healthy subjects (p<0.0001). PS and TAM RTK analysis plots are also presented in Figures 10 to 13.
[0063] With the invention, the detection and counting of markers at EV scale by flow cytometry paves the way for treatment methods targeting these molecules. In this way, monoclonal antibody applications or methods that selectively remove these molecules from the blood can be developed.
Claims
CLAIMS1. A method for measuring EV (extracellular vesicle) membrane protein levels in CLL patients by flow cytometry, characterised by comprising the steps purifying EVs from the plasma to be measured, - binding of CD9 (cluster of differentiation 9) antibodies to carboxy latex beads,- binding of the EVs to the carboxy latex beads by means of the CD9 antibodies, adding measurement antibodies that bind to target membrane proteins to the bead-CD9-EV complexes, determining measurement antibody levels by flow cytometry for the bead-CD9- EV-measurement antibody complex.
2. A method according to claim 1 characterized in that the measurement antibody is selected from among a CD81 (cluster of differentiation 81) protein antibody, a phosphatidylserine receptor tyrosine kinase antibody, a Tyro3 receptor tyrosine kinase antibody, an Axl receptor tyrosine kinase antibody and a Mertk receptor tyrosine kinase antibody.
